Intuitive Ventures

Medical robotics, especially in surgery, have been a very successful business for a few companies—especially?Intuitive Surgical—but many investors and inventors are disappointed that adoption of robotic technology has not lived up to the excitement that greeted Intuitive’s first?da Vinci?robotic assisted surgery system over 20 years ago. At the recent MedTech Strategist Innovation Summit in San Diego, three experts representing different perspectives on the industry talked about how robotics can improve clinical and economic outcomes and how companies developing medical robots can help customers realize that value. Featuring: ? Josh DeFonzo, Co-founder and CEO, Mendaera, Inc. ? Vivian Emmely Golfin, MD, Senior Associate, Intuitive Ventures ? David Noonan, Chief Technology Officer, Moon Surgical #medtech #medicaldevices #innovation #medicaltechnology #robotics

The number of medtech companies securing over $100 million in a single funding round reached double digits in 2024. Among these innovative companies are: Capstan Medical, securing $110 million to further develop its surgical robot and catheter-delivered implants for minimally invasive percutaneous replacement of mitral and tricuspid heart valves. Capstan hopes to conduct its first-in-human mitral valve procedure by early 2025. Amber Therapeutics, whose $100 million Series A was one of the largest Series A rounds ever in Europe for a medical technology company. Amber is developing adaptive neuromodulation technology to treat mixed urinary incontinence (MUI). https://lnkd.in/eRwJG6y6

“The IPO window has been limited in the MedTech space as of late. However, Ceribell’s IPO in 2024 suggests there could be room for transformative companies to go public in the coming years.”?— Vijay Rajasekhar, MD, MBA Vijay offers his insights on the MedTech IPO market for the new year in Fortune's Term Sheet. Check out the other predictions here: https://lnkd.in/e3cu4ra2

Congratulations to Maggie Nixon and the Capstan Medical team on the raise of a $110M Series C. Capstan is transforming the treatment of structural heart disease via endovascular robotics. Learn more about the company and why we invested here: https://lnkd.in/eTF7WGaF

Tomorrow Health Tech Forward kicks off in Barcelona. If you're attending, be sure to catch Murielle Thinard McLane's panel "Interoperability is the shortcut to better clinician efficiency and patient outcomes" alongside leaders from Digital Innovation GmbH, Amazon Web Services (AWS), Aster Hospitals UAE, and AXA Health. https://lnkd.in/diadRzv

This week, Vivian Emmely Golfin, MD attended MedTech Strategist's #InnovationSanDiego where she spoke on the panel "Raising Capital from Strategics." Joined by leaders from Edwards Lifesciences, Olympus Innovation Ventures, Johnson & Johnson MedTech, and Medtronic the keynote discussion focused on the medtech investment landscape.

Today, Jotthe Kannappan spoke on a panel at MedTech World's #MedTechMalta2024, discussing venture investment across the medtech landscape. If you’re attending tomorrow’s sessions, don’t miss the MedTech Startup Pitch Competition, where Jotthe will be one of the judges.

Today, Deloitte published Life Sciences and Healthcare Predictions 2030, featuring ten predictions on how the world could look in the next five years. The report highlights major trends in healthcare and life sciences, identifies key challenges to be addressed, and examines current evidence to forecast what the future may hold. Intuitive Ventures' $150 million Fund II - which was announced in late 2023 - was cited in the "Life sciences M&A, divestments and restructuring" section. Be sure to check out the full report here: https://lnkd.in/ewtX5jT4

Murielle Thinard McLane joined Amber Therapeutics, Lightstone Ventures, and Oxford Science Enterprises at LSI Europe this week, discussing Amber Therapeutics' $100M Series A and the future of neuromodulation for mixed urinary incontinence. Learn more about Amber Therapeutics and why Intuitive Ventures invested in the company here: https://lnkd.in/eXbSFimW

Highlights from Day 2-morning panels! We hit the ground running with four engaging panels this morning, featuring: Prosperity in Adversity: Doubling Down on Smart Investments in Uncertain Times ? Ido Hadari (Moderator) — Hadari Consulting ? Rafael Beyar — ALIVE Israel HealthTech Fund ? Assaf Barnea — Sanara Ventures ? Sharon Handelman-Gotlib —Shela Health ? Daniel Allen, PhD — Unorthodox Ventures Amber Therapeutics: $100M Series A, and the Future of Neuromodulation for Mixed Urinary Incontinence ? Henry Peck (Moderator) — LSI ? Aidan Crawley — Amber Therapeutics ? Caroline Gaynor — Lightstone Ventures ? Murielle Thinard McLane — Intuitive Ventures ? Liliane Chamas, PhD — Oxford Science Enterprises Medtech’s Conundrum: Where Will Capital and Liquidity Come From? ? Bill Little — Orchestra BioMed ? Michael Wasserman — Elevage Medical Technologies ? Alexander Schmitz — Endeavour Vision ? David Kereiakes — Windham Capital Partners ? Diana Saraceni — Panakes Partners Raising Capital from Family Offices ? Alexei Mlodinow — SIA ? Tyler Wanke — Wanke Family Office ? John Slump — Atraverse Medical ? Pablo Prieto — CG Health Ventures ? Marie-Louise Little — TW Medical A/S (Family Office) We’re about halfway through LSI Europe ‘24 - Still much more on the way. #LSIEurope24